Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
173 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape. H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 5, 14, 1, 30 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively. Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Influenza A Virus, H5N1 Subtype Infections - Overview 8 Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 19 Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment 20 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development 28 Akshaya Bio Inc 28 Altimmune Inc 28 Antigen Express Inc 29 Aphios Corp 29 BioDiem Ltd 30 BiondVax Pharmaceuticals Ltd 30 CEL-SCI Corp 31 Cocrystal Pharma Inc 31 Curevac AG 32 Fab'entech SA 32 Gemmus Pharma Inc 33 GlaxoSmithKline Plc 33 Hemispherx Biopharma Inc 34 iBio Inc 34 Inovio Pharmaceuticals Inc 35 Johnson & Johnson 35 Kineta Inc 36 Lakewood-Amedex Inc 36 Medicago Inc 37 Medigen Vaccine Biologics Corp 37 Microbiotix Inc 38 NanoBio Corp 38 Nanotherapeutics Inc 39 NanoViricides Inc 39 NewLink Genetics Corp 40 OPKO Health Inc 40 PaxVax Inc 41 PeptiDream Inc 41 Shionogi & Co Ltd 42 Takeda Pharmaceutical Company Ltd 43 TechnoVax Inc 43 TGV-Inhalonix Inc 44 Vaxart Inc 44 Vaxine Pty Ltd 45 VaxInnate Corp 45 Visterra Inc 46 Influenza A Virus, H5N1 Subtype Infections - Drug Profiles 47 AE-AI vaccine - Drug Profile 47 Alferon LDO - Drug Profile 48 APP-0205 - Drug Profile 50 APP-309 - Drug Profile 51 AT-301 - Drug Profile 52 CC-42344 - Drug Profile 53 CEL-1000 - Drug Profile 54 CHOS-05 - Drug Profile 56 DPC-005 - Drug Profile 57 FBF-001 - Drug Profile 58 Gamma-Flu - Drug Profile 59 GP-1001 - Drug Profile 60 GP-1002 - Drug Profile 61 GP-1681 - Drug Profile 62 GREFLU/VIE - Drug Profile 64 HAI-05 - Drug Profile 65 HB-36.6 - Drug Profile 67 Influ-nRNA - Drug Profile 68 influenza [strain A/H5N1] (split virion) vaccine - Drug Profile 69 influenza [strain A/H5N1] (virus like particle) vaccine 2 - Drug Profile 70 influenza [strain A/H5N1] vaccine - Drug Profile 73 influenza [strain A/H5N1] vaccine - Drug Profile 74 influenza [strain A/H5N1] vaccine - Drug Profile 75 influenza [strain A/H5N1] vaccine - Drug Profile 77 influenza [strain A/H5N1] vaccine - Drug Profile 78 influenza [strain A/H5N1] vaccine - Drug Profile 79 influenza [strain A/H5N1] vaccine - Drug Profile 80 influenza [strain A/H5N1] vaccine - Drug Profile 81 influenza [strain A/H5N1] vaccine - Drug Profile 82 influenza [strain A/H5N1] vaccine 2 - Drug Profile 83 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 84 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 85 influenza [strains A/H1N1 + A/H5N1] vaccine - Drug Profile 86 influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile 87 influenza [strains A/H5N1 + A/H7N2 + A/H9N2 + A/H7N3 + A/ H5N2] (virus like particle) vaccine - Drug Profile 88 influenza vaccine - Drug Profile 89 INO-3510 - Drug Profile 91 JNJ-3872 - Drug Profile 93 KD-295 - Drug Profile 96 KIN-1148 - Drug Profile 98 Lalistat - Drug Profile 100 M-001 - Drug Profile 101 MBX-2329 - Drug Profile 107 MBX-2546 - Drug Profile 108 Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection - Drug Profile 109 Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections - Drug Profile 110 MV-4 - Drug Profile 111 Nasovax - Drug Profile 112 NVINF-1 - Drug Profile 114 NVINF-2 - Drug Profile 119 OrniFlu - Drug Profile 122 PD-001 - Drug Profile 123 Peptides for Influenza Infections - Drug Profile 124 PNSIA-28 - Drug Profile 125 PNSIA-49 - Drug Profile 126 PXVX-0103 - Drug Profile 127 rintatolimod - Drug Profile 129 S-033188 - Drug Profile 139 Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile 141 Small Molecules to Activate Sirtuin for Influenza - Drug Profile 142 Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 143 Synthetic Peptides for Viral Infections - Drug Profile 144 TVX-003 - Drug Profile 145 VAX-161C - Drug Profile 146 VGX-3400X - Drug Profile 147 VH-244 - Drug Profile 149 VIS-410 - Drug Profile 150 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects 153 Influenza A Virus, H5N1 Subtype Infections - Discontinued Products 156 Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones 157 Featured News & Press Releases 157 Appendix 167 Methodology 167 Coverage 167 Secondary Research 167 Primary Research 167 Expert Panel Validation 167 Contact Us 167 Disclaimer 168
List of Tables
Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Antigen Express Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by BioDiem Ltd, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by CEL-SCI Corp, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Curevac AG, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Fab'entech SA, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Hemispherx Biopharma Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by iBio Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Johnson & Johnson, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Kineta Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medicago Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Microbiotix Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoBio Corp, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Nanotherapeutics Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoViricides Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by NewLink Genetics Corp, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by OPKO Health Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by PaxVax Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by PeptiDream Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Shionogi & Co Ltd, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by TechnoVax Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by TGV-Inhalonix Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxart Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxine Pty Ltd, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by VaxInnate Corp, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Visterra Inc, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H1 2017 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H1 2017 (Contd..2), H1 2017 Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.